• Mutation; HGNC; HGNC:11998; TP53; Simple; p.Cys242Tyr (c.725G>A); ClinVar=VCV000012354; Zygosity=Unspecified (PubMed=8393423).
  

PubMed=8393423; DOI=10.1002/hep.1840180216
Yano H., Iemura A., Fukuda K., Mizoguchi A., Haramaki M., Kojiro M.
Establishment of two distinct human hepatocellular carcinoma cell lines from a single nodule showing clonal dedifferentiation of cancer cells.
Hepatology 18:320-327(1993)

PubMed=7537711; DOI=10.1002/hep.1840210510
Haramaki M., Yano H., Fukuda K., Momosaki S., Ogasawara S., Kojiro M.
Expression of CD44 in human hepatocellular carcinoma cell lines.
Hepatology 21:1276-1284(1995)

PubMed=9023415; DOI=10.1006/cimm.1996.1062
Seki N., Hoshino T., Kikuchi M., Hayashi A., Itoh K.
HLA-A locus-restricted and tumor-specific CTLs in tumor-infiltrating lymphocytes of patients with non-small cell lung cancer.
Cell. Immunol. 175:101-110(1997)

PubMed=9178645; DOI=10.1006/cimm.1997.1108
Nakao M., Sata M., Saitsu H., Yutani S., Kawamoto M., Kojiro M., Itoh K.
CD4+ hepatic cancer-specific cytotoxic T lymphocytes in patients with hepatocellular carcinoma.
Cell. Immunol. 177:176-181(1997)

PubMed=10347112; DOI=10.1002/hep.510290624
Yano H., Iemura A., Haramaki M., Ogasawara S., Takayama A., Akiba J., Kojiro M.
Interferon alfa receptor expression and growth inhibition by interferon alfa in human liver cancer cell lines.
Hepatology 29:1708-1717(1999)

PubMed=27329724; DOI=10.18632/oncotarget.10161; PMCID=PMC5216950
Watari K., Nishitani A., Shibata T., Noda M., Kawahara A., Akiba J., Murakami Y., Yano H., Kuwano M., Ono M.
Phosphorylation of mTOR Ser2481 is a key target limiting the efficacy of rapalogs for treating hepatocellular carcinoma.
Oncotarget 7:47403-47417(2016)